ARCT Arcturus Therapeutics

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Alcobra, Ltd. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Alcobra, Ltd. (Nasdaq: ADHD) (“Alcobra” or the “Company”) securities during the period between August 13, 2015 and January 17, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 18, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Alcobra securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company’s statements regarding the MEASURE study discounted the results of the October 2014 Phase III Study, assumed that if extreme placebo response patients were removed from the analysis, a statistically significant trend in favor of metadoxine extended release would result, which did not, and were based upon disregarding Attention Deficit Hyperactivity Disorder patients who improved with a placebo.

According to the complaint, following a January 17, 2017 press release announcing that the MEASURE study failed to meet its primary endpoint, the value of Alcobra shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Alcobra securities purchased on or after August 13, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
28/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc: 1 director

A director at Arcturus Therapeutics Holdings Inc sold 50,000 shares at 32.030USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

 PRESS RELEASE

Arcturus Therapeutics to Present at Upcoming Investor and Scientific C...

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually: TIDES: Oligonucleotide and Peptide Therapeutics scientific conference PresentationDa...

 PRESS RELEASE

Arcturus Therapeutics Announces Preclinical Publication of its COVID-1...

Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination Clinical study remains on track, initial data readout expected Q4 2020 SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant ...

 PRESS RELEASE

Arcturus Therapeutics Executes Definitive Supply Agreement with the Is...

Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health, to supply C...

 PRESS RELEASE

Arcturus Therapeutics Announces that it has Initiated Dosing of its CO...

Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respirat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch